<DOC>
	<DOCNO>NCT00258596</DOCNO>
	<brief_summary>Primary intracoronary stent placement successfully cross chronic total occlusion ( CTO ) decrease high restenosis rate long-term follow-up compare conventional balloon angioplasty . Several study show efficacy sirolimus-eluting stent select group patient . Whether sirolimus-eluting stent superior bare metal stent CTO unknown . In prospective randomize trial , bare metal stent implantation compare sirolimus-eluting stent implantation treatment chronic total coronary occlusion . A total 200 patient follow 6 , 12 , 24 month angiographic follow-up 6 month . Quantitative coronary analysis perform independent core laboratory . The primary end point binary angiographic restenosis reocclusion rate 6 month follow-up .</brief_summary>
	<brief_title>Sirolimus-Eluting Stents Chronic Total Coronary Occlusions</brief_title>
	<detailed_description>Since data 2 landmark study , BENESTENT STRESS study , show coronary stenting significantly decrease restenosis compare conventional balloon angioplasty , treatment modality show superior increase number indication . Percutaneous coronary intervention chronic total occlusion ( CTO ) , however , still limit high restenosis rate . Although coronary stenting use bare metal stent significantly decrease restenosis CTO , restenosis rate still reach 32 % 55 % . In 200 patient CTO randomize PRISON I study , demonstrate restenosis rate 22 % bare metal stent implantation compare 33 % conventional balloon angioplasty . During past year , sirolimus ( rapamycin ) , cytostatic macrocyclic lactone anti-inflammatory antiproliferative property , deliver polymer-encapsulated stent show almost eliminate risk restenosis select group patient . In prospective , randomize , single-blind trial enrol 200 patient chronic total occlusion : 100 randomly assign receive bare metal BxVelocity™ stent , 100 receive sirolimus-eluting Cypher™ stent . The primary endpoint angiographic binary restenosis rate six month follow-up . Secondary endpoint composite major adverse cardiac event , target vessel failure , in-stent in-segment minimal lumen diameter , percentage diameter stenosis , late luminal loss six month follow-up . Clinical long-term follow-up perform till 24 month</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Stenosis</mesh_term>
	<mesh_term>Coronary Occlusion</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Estimated duration chronic total coronary occlusion least two week Evidence ischemia relate target vessel ( sign ischemia abnormal exercise test , define ST depression least 1.0 mm horizontal downsloping upsloping ST depression least 2.0 mm sign ischemia find nuclear imaging exercise , dobutamine adenosine ) . The lesion could cross The use heparin , aspirin clopidogrel prohibit Severe renal failure ( creatinine &gt; 250µmol/L ) Patients unwilling unable complete followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>drug-eluting stent</keyword>
	<keyword>chronic total occlusion</keyword>
	<keyword>sirolimus-eluting stent</keyword>
	<keyword>zotarolimus-eluting stent</keyword>
	<keyword>QCA</keyword>
</DOC>